These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 22536363)

  • 1. Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.
    Yu Y; Zhang L; Li X; Run X; Liang Z; Li Y; Liu Y; Lee MH; Grundke-Iqbal I; Iqbal K; Vocadlo DJ; Liu F; Gong CX
    PLoS One; 2012; 7(4):e35277. PubMed ID: 22536363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice.
    Hastings NB; Wang X; Song L; Butts BD; Grotz D; Hargreaves R; Fred Hess J; Hong KK; Huang CR; Hyde L; Laverty M; Lee J; Levitan D; Lu SX; Maguire M; Mahadomrongkul V; McEachern EJ; Ouyang X; Rosahl TW; Selnick H; Stanton M; Terracina G; Vocadlo DJ; Wang G; Duffy JL; Parker EM; Zhang L
    Mol Neurodegener; 2017 May; 12(1):39. PubMed ID: 28521765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiamet-G-mediated inhibition of O-GlcNAcase sensitizes human leukemia cells to microtubule-stabilizing agent paclitaxel.
    Ding N; Ping L; Shi Y; Feng L; Zheng X; Song Y; Zhu J
    Biochem Biophys Res Commun; 2014 Oct; 453(3):392-7. PubMed ID: 25268318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of Intracellular Tau Aggregation Regulated by OGA/OGT Inhibitors.
    Lim S; Haque MM; Nam G; Ryoo N; Rhim H; Kim YK
    Int J Mol Sci; 2015 Aug; 16(9):20212-24. PubMed ID: 26343633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
    Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
    Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo.
    Yuzwa SA; Macauley MS; Heinonen JE; Shan X; Dennis RJ; He Y; Whitworth GE; Stubbs KA; McEachern EJ; Davies GJ; Vocadlo DJ
    Nat Chem Biol; 2008 Aug; 4(8):483-90. PubMed ID: 18587388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiamme2-G, a Novel O-GlcNAcase Inhibitor, Reduces Tau Hyperphosphorylation and Rescues Cognitive Impairment in Mice.
    Pan D; Gu JH; Zhang J; Hu Y; Liu F; Iqbal K; Cekic N; Vocadlo DJ; Dai CL; Gong CX
    J Alzheimers Dis; 2021; 81(1):273-286. PubMed ID: 33814439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons.
    Takashima A; Honda T; Yasutake K; Michel G; Murayama O; Murayama M; Ishiguro K; Yamaguchi H
    Neurosci Res; 1998 Aug; 31(4):317-23. PubMed ID: 9809590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing O-GlcNAcylation Attenuates tau Hyperphosphorylation and Behavioral Impairment in rTg4510 Tauopathy Mice.
    Rostgaard N; Jul PH; Garmer M; Volbracht C
    J Integr Neurosci; 2023 Sep; 22(5):135. PubMed ID: 37735138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta.
    Qian W; Shi J; Yin X; Iqbal K; Grundke-Iqbal I; Gong CX; Liu F
    J Alzheimers Dis; 2010; 19(4):1221-9. PubMed ID: 20308788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MK-8719, a Novel and Selective
    Wang X; Li W; Marcus J; Pearson M; Song L; Smith K; Terracina G; Lee J; Hong KK; Lu SX; Hyde L; Chen SC; Kinsley D; Melchor JP; Rubins DJ; Meng X; Hostetler E; Sur C; Zhang L; Schachter JB; Hess JF; Selnick HG; Vocadlo DJ; McEachern EJ; Uslaner JM; Duffy JL; Smith SM
    J Pharmacol Exp Ther; 2020 Aug; 374(2):252-263. PubMed ID: 32493725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated O-GlcNAcylation stabilizes FOXM1 by its reduced degradation through GSK-3β inactivation in a human gastric carcinoma cell line, MKN45 cells.
    Inoue Y; Moriwaki K; Ueda Y; Takeuchi T; Higuchi K; Asahi M
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1681-1687. PubMed ID: 29196265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells.
    de Queiroz RM; Madan R; Chien J; Dias WB; Slawson C
    J Biol Chem; 2016 Sep; 291(36):18897-914. PubMed ID: 27402830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners.
    Liu F; Liang Z; Shi J; Yin D; El-Akkad E; Grundke-Iqbal I; Iqbal K; Gong CX
    FEBS Lett; 2006 Nov; 580(26):6269-74. PubMed ID: 17078951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.
    Shi HR; Zhu LQ; Wang SH; Liu XA; Tian Q; Zhang Q; Wang Q; Wang JZ
    J Neural Transm (Vienna); 2008 Jun; 115(6):879-88. PubMed ID: 18217188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based discovery and development of novel O-GlcNAcase inhibitors for the treatment of Alzheimer's disease.
    Li X; Han J; Bujaranipalli S; He J; Kim EY; Kim H; Im JH; Cho WJ
    Eur J Med Chem; 2022 Aug; 238():114444. PubMed ID: 35588599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The O-GlcNAc Modification of Recombinant Tau Protein and Characterization of the O-GlcNAc Pattern for Functional Study.
    El Hajjar L; Bridot C; Nguyen M; Cantrelle FX; Landrieu I; Smet-Nocca C
    Methods Mol Biol; 2024; 2754():237-269. PubMed ID: 38512671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genetic model to study
    St Amand MM; Bond MR; Riedy J; Comly M; Shiloach J; Hanover JA
    J Biol Chem; 2018 Aug; 293(35):13673-13681. PubMed ID: 29954943
    [No Abstract]   [Full Text] [Related]  

  • 19. Acutely elevated O-GlcNAcylation suppresses hippocampal activity by modulating both intrinsic and synaptic excitability factors.
    Hwang H; Rhim H
    Sci Rep; 2019 May; 9(1):7287. PubMed ID: 31086206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of AKT by O-linked N-acetylglucosamine induces vascular calcification in diabetes mellitus.
    Heath JM; Sun Y; Yuan K; Bradley WE; Litovsky S; Dell'Italia LJ; Chatham JC; Wu H; Chen Y
    Circ Res; 2014 Mar; 114(7):1094-102. PubMed ID: 24526702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.